

## TABLE OF CONTENTS

<b>LIST OF ABBREVIATIONS.....</b>	<b>IV</b>
<b>1. INTRODUCTION.....</b>	<b>1</b>
<b>1.1 Aim of the application .....</b>	<b>1</b>
<b>1.2 Epidemiologic background .....</b>	<b>1</b>
<b>1.3 Pathophysiology of ACS.....</b>	<b>1</b>
<b>1.4 Basic treatment for ACS .....</b>	<b>2</b>
<b>1.5 Direct thrombin inhibition with hirudin.....</b>	<b>2</b>
<b>1.6 Characteristics and clinical pharmacology of lepirudin .....</b>	<b>3</b>
<b>2. CLINICAL TRIAL PROGRAM FOR LEPIRUDIN IN ACS.....</b>	<b>4</b>
<b>2.1 Overview of the program .....</b>	<b>4</b>
<b>2.2 Study design of the OASIS studies .....</b>	<b>4</b>
2.2.1 OASIS-1 .....	4
2.2.2 OASIS-2 .....	7
<b>2.3 Characteristics of the patients in the OASIS studies .....</b>	<b>10</b>
<b>2.4 Exposure to study medication in the OASIS studies .....</b>	<b>13</b>
<b>3. DOSE FINDING.....</b>	<b>14</b>
<b>3.1 Phase IIa studies (APT-1 and PTCA study).....</b>	<b>14</b>
<b>3.2 OASIS-1 .....</b>	<b>15</b>
<b>3.3 Conclusion .....</b>	<b>17</b>
<b>4. THE EFFICACY OF LEPIRUDIN COMPARED TO UNFRACTIONATED     HEPARIN.....</b>	<b>18</b>
<b>4.1 OASIS-1 results.....</b>	<b>18</b>
<b>4.2 OASIS-2 .....</b>	<b>21</b>
4.2.1 Key analyses of efficacy .....	22
4.2.1.1 Primary analysis of efficacy .....	22
4.2.1.2 Key secondary analysis of efficacy .....	22
4.2.1.3 Benefit of lepirudin in the first 72 hours .....	22
4.2.1.4 Comparability across study populations.....	23
4.2.1.5 Incidence of individual endpoint components.....	23
4.2.1.6 Preservation of benefit of lepirudin over time.....	24
4.2.1.7 Confirmation rates in the adjudication process .....	26
4.2.1.8 Patients lost to follow-up.....	26
4.2.2 Supportive analyses of efficacy .....	26
4.2.2.1 All-cause mortality .....	26
4.2.2.2 Non-parametric analyses of covariance.....	27
4.2.2.3 Subgroup analyses of efficacy.....	27
4.2.2.4 CV death, new MI, or refractory or severe angina .....	31
4.2.2.5 Associated MI .....	31
4.2.2.6 Periprocedural MI.....	31
4.2.2.7 Cardiac interventions.....	32
4.2.2.8 Radiological evidence of heart failure.....	34
4.2.2.9 aPTT .....	35
4.2.2.10 Warfarin substudy analyses.....	36
<b>4.3 OASIS-1&amp;2 combined results.....</b>	<b>37</b>

4.4	<b>OASIS-1&amp;2 in the perspective of other hirudin trials</b> .....	39
4.4.1	Characteristics of hirudins .....	39
4.4.2	Data from other hirudin trials .....	39
4.4.3	Comparison of combined OASIS studies with GUSTO-2b non-ST.....	40
4.5	<b>Comparison of hirudin with alternative products</b> .....	41
4.5.1	Comparison of primary endpoints across ACS studies.....	42
4.5.2	Comparison of relative risks across ACS studies .....	43
5.	<b>THE EFFICACY OF LEPIRUDIN COMPARED TO A ‘PUTATIVE PLACEBO’</b> .....	45
5.1	<b>Introduction and purpose</b> .....	45
5.2	<b>Selection of heparin + aspirin vs. placebo + aspirin studies</b> .....	45
5.3	<b>Statistical approaches for deriving lepirudin vs. putative placebo effect</b> .....	46
5.4	<b>Results: historical estimate of heparin + aspirin vs. aspirin alone effect</b> .....	47
5.5	<b>Results: direct estimation - lepirudin vs. ‘putative placebo’ comparison (lepirudin + aspirin versus aspirin alone)</b> .....	47
5.6	<b>Results: Sensitivity analysis estimating outcome if there had been a placebo control group in the OASIS-2</b> .....	48
5.7	<b>Conclusions</b> .....	50
6.	<b>THE SAFETY OF LEPIRUDIN</b> .....	51
6.1	<b>Design aspects</b> .....	51
6.2	<b>Major and minor bleeds</b> .....	52
6.2.1	OASIS-1 .....	52
6.2.2	OASIS-2 .....	53
6.2.3	Comparison with alternative products .....	55
6.2.4	Conclusions .....	56
6.3	<b>Stroke</b> .....	56
6.3.1	OASIS-1 .....	56
6.3.2	OASIS-2 .....	57
6.3.3	Comparison with published literature data .....	58
6.3.4	Conclusions .....	58
6.4	<b>Overview of all adverse events</b> .....	59
6.4.1	OASIS-1 .....	59
6.4.2	OASIS-2 .....	59
6.5	<b>Laboratory variables</b> .....	62
7.	<b>RISK/BENEFIT ASSESSMENT</b> .....	63
8.	<b>SUMMARY AND CONCLUSIONS</b> .....	65
8.1	<b>Efficacy vs. heparin</b> .....	65
8.2	<b>Efficacy vs. placebo</b> .....	66
8.3	<b>Safety profile</b> .....	66
8.4	<b>Risk/benefit ratio</b> .....	67
8.5	<b>Therapeutic justification</b> .....	67
8.6	<b>Recommended dosage and duration of therapy</b> .....	67
9.	<b>LITERATURE LIST</b> .....	69

## LIST OF ABBREVIATIONS

aPTT	Activated partial thromboplastin time
ACS	Acute coronary syndromes
AE	Adverse event
APT-1	Antithrombin Preinfarction Trial 1
CABG	Coronary artery bypass graft
CAD	Coronary artery disease
CCC	Canadian Cardiovascular Collaboration
CI	Confidence interval
CV	Cardiovascular
HIT	Heparin-induced thrombocytopenia
ITT	Intention-to-treat
LMW	Low-molecular-weight
MI	Myocardial infarction
MITT	Modified intention-to-treat
OASIS	Organization to Assess Strategies for Ischemic Syndromes
PCI	Percutaneous coronary intervention
PTCA	Percutaneous transluminal coronary angioplasty
RR	Relative risk
SAP	Statistical analysis plan